Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12563197 | 0.80 | LMNA (0.43) | LMNACHRNB4CHRNA3ATML3MBTL1 | |
| SCHEMBL13105272 | 0.80 | CHRNB4 (0.45) | LMNACHRNB4CHRNA3ATML3MBTL1 | |
| SCHEMBL13067181 | 0.80 | CHRNB4 (0.45) | LMNACHRNB4CHRNA3ATML3MBTL1 | |
| SCHEMBL19362506 | 0.80 | CHRNB4 (0.45) | LMNACHRNB4CHRNA3ATML3MBTL1 | |
| SCHEMBL13676359 | 0.79 | LMNA (0.56) | LMNAATML3MBTL1CHRM3KDM4E | |
| SCHEMBL13676375 | 0.79 | LMNA (0.56) | LMNAATML3MBTL1CHRM3KDM4E | |
| SCHEMBL28385294 | 0.77 | LMNA (0.38) | LMNAATML3MBTL1CHRM3 | |
| SCHEMBL24621749 | 0.71 | NUDT1 (0.35) | — | |
| SCHEMBL27163807 | 0.68 | PLA2G1B (0.45) | LMNACHRNB4CHRNA3L3MBTL1CYP3A4 | |
| SCHEMBL27163810 | 0.68 | PLA2G1B (0.45) | LMNACHRNB4CHRNA3L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179242-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20100256329-A1 | STEREOSELECTIVE ALTERNATING COPOLYMERIZATION OF EPOXIDE WITH CARBON DIOXIDE | THE UNIVERSITY OF TOKYO (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179242-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | LMNA 3764/4885CHRNB4 2123/4885CHRNA3 2761/4885 |
| US-20100256329-A1 | STEREOSELECTIVE ALTERNATING COPOLYMERIZATION OF EPOXIDE WITH CARBON DIOXIDE | PCNA, HPD, TET3 | LMNA 3481/4885CHRNB4 443/4885CHRNA3 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.